extended-release MetAP2 inhibitor APL-1501

{
  "id": "MLC-T-ONC-013493",
  "term": "extended-release MetAP2 inhibitor APL-1501",
  "field": "Oncology and biomedicine",
  "definition": "An extended-release (ER) formulation of APL-1501, an orally available inhibitor of methionine aminopeptidase II type (MetAP2), with potential antiangiogenic and antineoplastic activities. Upon administration, ER MetAP2 inhibitor APL-1501 is released from the formulation over an extended period of time and targets, binds to and reversibly inhibits MetAP2, thereby preventing MetAP2-mediated signal transduction pathways. This may suppress endothelial cell growth and inhibit tumor angiogenesis, resulting in tumor cell death. MetAP2, a member of the dimetallohydrolase family, is upregulated in certain tumor cell types and plays a key role in angiogenesis, proliferation and survival. Compared to APL-1202, APL-1501 has improved pharmacokinetic (PK) characteristics. The ER formulation allows for controlled drug release, enhanced drug plasma exposure time and reduced medication intake frequency.",
  "synonyms": [
    "ER APL1501",
    "ER APL 1501",
    "ER APL-1501",
    "ethionine aminopeptidase type II inhibitor APL-1501"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/extended-release-metap2-inhibitor-apl-1501/"
}